Palifermin After Haploidentical PBSCT

Inclusion Criteria: Recipient: * Chemosensitive low/high grade B-NHL or T-NHL, Multiple Myeloma (MM) in partial or complete remission * ALL and AML, secondary AML and biphenotypic acute leukemia in complete remission (CR1 or CR2) or PR (only if ≤20% blasts in BM), Myelodysplastic syndrome (MDS) * CML in chronic or accelerated phase * Osteomyelofibrosis (OMF) * Hodgkin lymphoma (HD) in partial or complete remission * Age ≥18 years, ≤ 65 years * ECOG status ≤2 * Prior treatment with 3 or less different chemotherapy regimens (not cycles); prior local radiotherapy is allowed except radiation involving the thymus * Adequate pulmonary function * Left ventricular ejection fraction (LVEF) \>30% * Haploidentical related donor * Failure to find matched related or matched unrelated donor and urgently requiring transplantation * Planned conditioning regimen per Aversa or Würzburg protocol * Women must be post-menopausal, sterile or use effective contraception and have a negative pregnancy test at study entry (β-HCG neg) * Signed informed consent Donor: * Healthy family member * Selection based on typing of HLA-A, B, C, DR loci. Donor must be at least genotypically HLA-A, B, C, DR haploidentical to the patient, but must differ for 2-3 HLA allele(s) on the unshared haplotype * Donors must be capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central venous catheter should leukapheresis via peripheral vein be inadequate. * Donors must agree to a 2nd donation of PBPCs in case of insufficient CD34+ cell collection or should patient fail to demonstrate sustained engraftment * Signed informed consent Exclusion Criteria: Recipient: * History of or concurrent cancer (\< 5 years ago) other than those named in inclusion criteria * Primary chemorefractory disease * CML in blast crisis * MM with no or minor response to previous treatment * Prior treatment with palifermin, or other keratinocyte growth factors * Documented hypersensitivity to palifermin, E. coli-derived proteins, or any component of the product * Documented hypersensitivity to Prevenar vaccine or its components * Prior allogeneic or tandem PBPC transplantation (no more than 1 previous autologous transplantation * Prior total body irradiation * Post thymectomy * Major anticipated illness or organ failure incompatible with survival from PBPC transplantation * Active chronic skin disease requiring therapy * Active inflammatory bowel disease requiring therapy * Active uncontrolled infection * Sero-positive HIV * Pregnancy or breast-feeding * Active invasive fungal tissue infection (EORTC criteria) * 30 days or less since receiving an investigational product or device in another clinical trial * Concurrent enrolment in another trial is not permitted unless the purpose is for long-term follow-up/survival data only, or observational only * Chronic pancreatitis or history of acute pancreatitis within 1 year prior to transplant * Psychiatric disorder associated with incompliance * Myocardial infarction less than 3 months pre enrolment or EF \<30% as measured in echocardiography/laevoventriculography * Infusion of retrovirally or other transduced cells are not permitted. * Planned intravenous application of immunoglobulins is contraindicated throughout the study period. * Donor lymphocyte infusions are not allowed. Donor: * A positive HIV or HTLV-1 test or evidence of active/persistent viral hepatitis infection. * Evidence of any other active infection * Any medical condition (i.e. insulin-dependent diabetes, cardiovascular disorders, chronic inflammatory diseases) posing a health risk for peripheral blood stem cell harvest * Hematopoietic or marrow function related disease interfering with the collection of sufficient numbers of normal progenitor cells * Pregnancy or breast-feeding * Any malignancy besides basal cell epithelioma or cured malignancy \< 5 years ago * Psychiatric disorder associated with incompliance